 <h1>Jasmiel Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>drospirenone / ethinyl estradiol</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about drospirenone / ethinyl estradiol. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Jasmiel.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to drospirenone / ethinyl estradiol: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Women who are over 35 years of age and smoke should not use oral contraceptives.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, drospirenone / ethinyl estradiol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking drospirenone / ethinyl estradiol:</p><p>
<i>More common</i>
</p><ul>
<li>Breast pain or tenderness</li>
<li>headache, severe and throbbing</li>
<li>heavy non-menstrual vaginal bleeding</li>
<li>irregular menstrual periods</li>
<li>nausea</li>
<li>normal menstrual bleeding occurring earlier, possibly lasting longer than expected</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Longer or heavier menstrual periods</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Chills</li>
<li>clay-colored stools</li>
<li>dark urine</li>
<li>difficulty with breathing</li>
<li>dizziness</li>
<li>fever</li>
<li>headache</li>
<li>itching</li>
<li>loss of appetite</li>
<li>pain in the chest, groin, or legs, especially the calves</li>
<li>rash</li>
<li>slurred speech</li>
<li>stomach pain</li>
<li>sudden loss of coordination</li>
<li>sudden, severe weakness or numbness in the arm or leg</li>
<li>unpleasant breath odor</li>
<li>unusual tiredness or weakness</li>
<li>vision changes</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of drospirenone / ethinyl estradiol may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Crying</li>
<li>decreased interest in sexual intercourse</li>
<li>delusions of persecution, mistrust, suspiciousness, or combativeness</li>
<li>false or unusual sense of well-being</li>
<li>inability to have or keep an erection</li>
<li>irritability</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>mental depression</li>
<li>quick to react or overreact emotionally</li>
<li>rapidly changing moods</li>
<li>weight gain</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to drospirenone / ethinyl estradiol: oral tablet</i></p><h3>General</h3><p>The most common adverse events were irregular uterine bleeding, nausea, breast tenderness, and headache.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Breast pain or discomfort (17.9%), menstrual disorders (17%), female genital tract bleeding (14%), premenstrual syndrome (13.2%)</p>
<p><b>Common</b> (1% to 10%): Vaginal candidiasis, leukorrhea, intermenstrual bleeding, cystitis, unscheduled uterine bleeding/genital tract bleeding NOS, metrorrhagia, amenorrhea, breast tenderness, vaginal discharge, cervical polyp </p>
<p><b>Uncommon</b> (0.1% to 1%): Vaginitis, pelvic pain, breast enlargement, fibrocystic breast, genital discharge, dysmenorrhea, hypomenorrhea, menorrhagia, vaginal dryness, Pap smear suspicious, breast hypertrophy</p>
<p><b>Rare</b> (less than 0.1%): Dyspareunia, vulvovaginitis, postcoital bleeding, withdrawal bleeding, breast cyst, breast hyperplasia, endometrial atrophy, ovarian cyst, uterine enlargement, breast discharge</p>
<p><b>Frequency not reported</b>: Cervical dysplasia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects have included nausea, which occurs in approximately 10% of treated women and may be more frequent during the first cycles of therapy.  Some early reports suggested an association between oral contraceptive use and gallbladder disease.  Abdominal pain and gastroenteritis have been reported in postmarketing experience.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Venous and arterial thromboembolic events includes peripheral deep vein occlusion, thrombosis and embolism/pulmonary vascular occlusion, thrombosis, embolism, infarction, intracardiac thrombosis, retinal vein occlusion, myocardial infarction, cerebral infarction, and stroke.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Hypertension, hypotension, varicose vein</p>
<p><b>Rare</b> (less than 0.1%): Venous and arterial thromboembolic events, tachycardia, vascular disorder, phlebitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (20%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, migraine</p>
<p><b>Uncommon</b> (0.1% to 1%): Somnolence, dizziness, paresthesia, asthenia</p>
<p><b>Rare</b> (less than 0.1%): Vertigo, tremor, syncope<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression/depressive mood, nervousness, emotional lability, decrease and loss of libido, libido increased, affect lability</p>
<p><b>Rare</b> (less than 0.1%): Anorgasmia, insomnia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue</p>
<p><b>Uncommon</b> (0.1% to 1%): Weight gain, weight loss, hot flushes, edema (generalized)</p>
<p><b>Rare</b> (less than 0.1%): Candidiasis, malaise, hypoacusis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Acne</p>
<p><b>Uncommon</b> (0.1% to 1%): Pruritus, rash, increased sweating, eczema, alopecia</p>
<p><b>Rare</b> (less than 0.1%): Chloasma, dermatitis acneiform, dry skin, erythema nodosum, erythema multiforme, hypertrichosis, skin disorder, skin striae, contact dermatitis, photosensitive dermatitis, skin nodule </p>
<p><b>Postmarketing reports</b>: Angioedema<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pharyngitis, sinusitis</p>
<p><b>Rare</b> (less than 0.1%): Epistaxis, asthma<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Hypersensitivity, allergic reaction<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Rare</b> (less than 0.1%): Breast neoplasm, breast cancer, focal nodular hyperplasia</p>
<p><b>Frequency not reported</b>: Uterine leiomyoma </p>
<p><b>Postmarketing reports</b>: Liver tumors<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (less than 0.1%): Biliary pain, cholecystitis acute</p>
<p><b>Postmarketing reports</b>: Gallbladder disease, liver function disturbances<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Fluid retention</p>
<p><b>Rare</b> (less than 0.1%): Increased appetite, anorexia, hyperkalemia, hyponatremia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Back pain, pain in extremity, muscle cramps</p>
<p><b>Postmarketing reports</b>: Systemic lupus erythematosus<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (less than 0.1%): Conjunctivitis, dry eye, eye disorder, contact lens intolerance<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (less than 0.1%): Anemia, thrombocythemia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Rare</b> (less than 0.1%): Endocrine disorder<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Yasmin (drospirenone-ethinyl estradiol)" Berlex Laboratories, Richmond, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Gianvi (drospirenone-ethinyl estradiol)." Teva Pharmaceuticals USA, North Wales, PA. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Jasmiel (drospirenone / ethinyl estradiol)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>2 Reviews</li>
<li>Drug class: contraceptives</li>
<li>FDA Alerts (5)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Yaz, Yasmin, Gianvi, Ocella, ... +5 more</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acne</li>
<li>Premenstrual Dysphoric Disorder</li>
<li>Birth Control</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to drospirenone / ethinyl estradiol: oral tablet</i></p><h3>General</h3><p>The most common adverse events were irregular uterine bleeding, nausea, breast tenderness, and headache.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Breast pain or discomfort (17.9%), menstrual disorders (17%), female genital tract bleeding (14%), premenstrual syndrome (13.2%)</p><p><b>Common</b> (1% to 10%): Vaginal candidiasis, leukorrhea, intermenstrual bleeding, cystitis, unscheduled uterine bleeding/genital tract bleeding NOS, metrorrhagia, amenorrhea, breast tenderness, vaginal discharge, cervical polyp </p><p><b>Uncommon</b> (0.1% to 1%): Vaginitis, pelvic pain, breast enlargement, fibrocystic breast, genital discharge, dysmenorrhea, hypomenorrhea, menorrhagia, vaginal dryness, Pap smear suspicious, breast hypertrophy</p><p><b>Rare</b> (less than 0.1%): Dyspareunia, vulvovaginitis, postcoital bleeding, withdrawal bleeding, breast cyst, breast hyperplasia, endometrial atrophy, ovarian cyst, uterine enlargement, breast discharge</p><p><b>Frequency not reported</b>: Cervical dysplasia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects have included nausea, which occurs in approximately 10% of treated women and may be more frequent during the first cycles of therapy.  Some early reports suggested an association between oral contraceptive use and gallbladder disease.  Abdominal pain and gastroenteritis have been reported in postmarketing experience.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Venous and arterial thromboembolic events includes peripheral deep vein occlusion, thrombosis and embolism/pulmonary vascular occlusion, thrombosis, embolism, infarction, intracardiac thrombosis, retinal vein occlusion, myocardial infarction, cerebral infarction, and stroke.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Hypertension, hypotension, varicose vein</p><p><b>Rare</b> (less than 0.1%): Venous and arterial thromboembolic events, tachycardia, vascular disorder, phlebitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (20%)</p><p><b>Common</b> (1% to 10%): Dizziness, migraine</p><p><b>Uncommon</b> (0.1% to 1%): Somnolence, dizziness, paresthesia, asthenia</p><p><b>Rare</b> (less than 0.1%): Vertigo, tremor, syncope<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression/depressive mood, nervousness, emotional lability, decrease and loss of libido, libido increased, affect lability</p><p><b>Rare</b> (less than 0.1%): Anorgasmia, insomnia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue</p><p><b>Uncommon</b> (0.1% to 1%): Weight gain, weight loss, hot flushes, edema (generalized)</p><p><b>Rare</b> (less than 0.1%): Candidiasis, malaise, hypoacusis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Acne</p><p><b>Uncommon</b> (0.1% to 1%): Pruritus, rash, increased sweating, eczema, alopecia</p><p><b>Rare</b> (less than 0.1%): Chloasma, dermatitis acneiform, dry skin, erythema nodosum, erythema multiforme, hypertrichosis, skin disorder, skin striae, contact dermatitis, photosensitive dermatitis, skin nodule </p><p><b>Postmarketing reports</b>: Angioedema<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pharyngitis, sinusitis</p><p><b>Rare</b> (less than 0.1%): Epistaxis, asthma<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Hypersensitivity, allergic reaction<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Rare</b> (less than 0.1%): Breast neoplasm, breast cancer, focal nodular hyperplasia</p><p><b>Frequency not reported</b>: Uterine leiomyoma </p><p><b>Postmarketing reports</b>: Liver tumors<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (less than 0.1%): Biliary pain, cholecystitis acute</p><p><b>Postmarketing reports</b>: Gallbladder disease, liver function disturbances<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Fluid retention</p><p><b>Rare</b> (less than 0.1%): Increased appetite, anorexia, hyperkalemia, hyponatremia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Back pain, pain in extremity, muscle cramps</p><p><b>Postmarketing reports</b>: Systemic lupus erythematosus<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (less than 0.1%): Conjunctivitis, dry eye, eye disorder, contact lens intolerance<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (less than 0.1%): Anemia, thrombocythemia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Rare</b> (less than 0.1%): Endocrine disorder<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Yasmin (drospirenone-ethinyl estradiol)" Berlex Laboratories, Richmond, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Gianvi (drospirenone-ethinyl estradiol)." Teva Pharmaceuticals USA, North Wales, PA. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about Jasmiel (drospirenone / ethinyl estradiol)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>2 Reviews</li>
<li>Drug class: contraceptives</li>
<li>FDA Alerts (5)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acne</li>
<li>Premenstrual Dysphoric Disorder</li>
<li>Birth Control</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>